The headline out of the United Nations this week was reassurance: world leaders, gathered in New York, publicly renewed their commitment to protecting the world from the next pandemic. It is the kind of statement that is easy to applaud and easy to forget. But underneath the commitment sits an uncomfortable fact that deserves more attention than the ceremony did — the international agreement those leaders were rallying behind is not actually finished, and the piece still missing is one of the most consequential parts of the whole thing.
What leaders actually committed to
According to the WHO's account of the September 25 high-level meeting, the gathering was a political recommitment: heads of state and senior officials reaffirming that pandemic preparedness remains a priority and that the world should not repeat the fractured, every-country-for-itself response that marked recent history. Political recommitment matters. It signals intent, keeps the issue on the agenda, and can unlock attention and, sometimes, money. But a recommitment is a promise about the future, not a mechanism that changes anything on its own.
The agreement behind the ceremony
The substance the meeting pointed to is the WHO Pandemic Agreement, the international instrument negotiated in the wake of COVID-19 to govern how countries prepare for and respond to pandemics together. Its ambitions span the things that broke down last time: sharing information, coordinating research, strengthening health systems, and — critically — making sure that when the next dangerous pathogen appears, both the pathogen data and the resulting benefits, such as vaccines and treatments, are shared more fairly than they were.
That last aim is where the agreement is at once most important and most unfinished.
The piece that is still being written
The mechanism meant to deliver that fairer sharing is a specific annex on Pathogen Access and Benefit-Sharing — usually shortened to PABS. In plain terms, PABS is meant to formalize a bargain: countries and laboratories share samples and genetic-sequence data of emerging pathogens quickly and openly, and in exchange they get a more reliable, more equitable claim on the vaccines, tests, and treatments developed from that shared material. It is the part of the agreement designed to prevent a repeat of the scramble in which wealthier countries secured supplies first and much of the world waited.
And it is not done. The PABS annex remains under negotiation, worked through by an intergovernmental process rather than settled by the agreement's adoption. This is the crucial thing to be precise about: the broader agreement can exist while its benefit-sharing engine is still being built. Treating PABS as already agreed, or as a settled guarantee of equitable access, would misrepresent where things actually stand. It is a target, not yet a finished rule.
Why an unfinished annex is not a technicality
It would be easy to file PABS under bureaucratic housekeeping. That would be a mistake. The benefit-sharing annex is, in many ways, the test of whether the whole agreement means what it says. The preparedness commitments are relatively easy to endorse in principle; the hard part — the part that determines who lives and who waits during the next emergency — is the enforceable arrangement for sharing access. Until that annex is finalized, the agreement's central equity promise remains aspirational.
The negotiations are difficult precisely because the stakes are real. They touch on national sovereignty over biological samples, the commercial interests of manufacturers, intellectual property, and the obligations of governments to one another. None of that is resolved by a show of political will at a summit.
The milestone to watch
The process is oriented toward a milestone at the World Health Assembly — the annual decision-making meeting of WHO's member states — with attention now on the May 2027 Assembly as a point by which countries aim to have the outstanding pieces, including the benefit-sharing arrangements, advanced enough for the agreement to move toward signature and ratification. Even that framing carries caveats: an international agreement of this kind typically has to be adopted, then signed, then ratified by enough countries before it legally enters into force. Each of those steps is a separate hurdle, and each can slip.
Commitments versus financed capacity
There is a second gap that this week's ceremony did little to close, and it is the one an accountability lens keeps returning to: the distance between political commitments and financed national capacity. A treaty can require preparedness; it cannot, by itself, staff a laboratory in an under-resourced country, pay disease-surveillance officers, or maintain the boring, continuous infrastructure that detects an outbreak early. Those things cost money, year after year, in exactly the kind of unglamorous budget lines that are easy to cut between crises.
So the question worth asking after any renewed commitment is not whether leaders said the right words. It is whether the words are attached to durable funding and to a finished, enforceable benefit-sharing rule. On both counts, the honest answer right now is: not yet.
The bottom line
Renewed political will is worth having, and it is easy to be cynical about summits. But accountability means holding the gap between promise and mechanism in view. The Pandemic Agreement's benefit-sharing annex is unfinished, the path to ratification runs through milestones that have not yet been cleared, and financed national capacity still trails the rhetoric. Those are not reasons for despair; they are the specific, trackable things to watch — and to keep asking about — long after the meeting's statements have scrolled off the news.